FIELD: medicine; oncology; therapy.
SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology and therapy; it is intended for the treatment of estrogen-receptor-positive breast cancer in a subject who needs it. The treatment method includes administration to the specified subject of therapeutically effective amount of a compound capable of inhibiting MPS1, wherein the specified subject was previously treated with CDK4/6 inhibitor, and/or the specified breast cancer is resistant to the treatment with CDK4/6 inhibitor. Applications of a compound capable of inhibiting MPS1 for the treatment of estrogen-receptor-positive breast cancer in a subject and for the production of a drug for the treatment of estrogen-receptor-positive breast cancer in a subject are also presented.
EFFECT: use of the group of inventions provides effective treatment of estrogen-receptor-positive breast cancer.
87 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| N2-(2-PHENYL)-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND USE THEREOF AS MPS1 INHIBITOR | 2015 |
|
RU2693460C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2016 |
|
RU2695337C2 |
| BENZOPYRAZINE AND BENZOXEPINE PI3K INHIBITORS AND USE THEREOF | 2009 |
|
RU2506267C2 |
| 2-(PHENYL OR PYRID-3-YL)AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-RICH REPEATING KINASE 2 (LRRK2) FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2647849C2 |
| CONDENSED 4-OXOPYRIMIDINE DERIVATIVE | 2005 |
|
RU2358969C2 |
| HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
| AKT ACTIVITY INHIBITORS | 2006 |
|
RU2421454C2 |
| DIAMINOTRIAZOLES, SUITABLE AS INHIBITORS OF PROTEIN KINASES | 2003 |
|
RU2350606C2 |
